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The protein NOS1AP/CAPONmediates signaling from a protein complex of NMDA receptor, PSD95 and nNOS. The only stroke trial for
neuroprotectants that showedbenefit to patients targeted this ternary complex.NOS1AP/nNOS interaction regulates small GTPases, iron
transport, p38MAPK-linked excitotoxicity, and anxiety. Moreover, the nos1ap gene is linked to disorders from schizophrenia, post-
traumatic stress disorder, and autism to cardiovascular disorders and breast cancer. Understanding protein interactions required for
NOS1AP function, therefore, has broad implications for numerous diseases. Here we show that the interaction of NOS1AP with nNOS
differs radically from the classical PDZ docking assumed to be responsible. The NOS1AP PDZmotif does not bind nNOS asmeasured by
multiple methods. In contrast, full-length NOS1AP forms an unusually stable interaction with nNOS. We mapped the discrepancy
between full-length andC-terminal PDZmotif to anovel internal regionwecall theExFmotif. TheC-terminal PDZmotif, althoughneither
sufficient nor necessary for binding, nevertheless promotes the stability of the complex. It therefore potentially affects signal transduc-
tion and suggests that functional interaction of nNOS with NOS1AP might be targetable at two distinct sites. We demonstrate that
excitotoxic pathways can be regulated, in cortical neuron and organotypic hippocampal slice cultures from rat, either by the previously
describedPDZ ligandTAT-GESVorby theExFmotif-bearing regionofNOS1AP, evenwhen lacking the critical PDZresidues as longas the
ExF motif is intact and not mutated. This previously unrecognized heterodivalent interaction of nNOS with NOS1AP may therefore
provide distinct opportunities for pharmacological intervention in NOS1AP-dependent signaling and excitotoxicity.
Key words: excitotoxic lesion; NMDA receptor; nNOS/NOS1; NOS1AP/CAPON; protein interaction; target identification
Introduction
NOS1AP (also known as CAPON) recently emerged as a poten-
tial player in conditions from cerebral ischemia, anxiety disor-
ders, and schizophrenia to diabetes and sudden cardiac death.
Mechanistic studies suggest that interaction of NOS1AP with
nNOS contributes to NOS1AP-mediated excitotoxicity (Li et al.,
2013; Lai et al., 2014), cardiac action potential duration (Chang et
al., 2008), elaboration of neuronal processes (Carrel et al., 2009),
and possibly schizophrenia (Xu et al., 2005).
PDZ interactions are well understood; a peptide ligand of 4 or
5 amino acids with specific conserved C-terminal residues docks
in the binding pocket of a90 amino acid domain (Doyle et al.,
1996; Harris and Lim, 2001). The mechanism of interaction of
NOS1APwith nNOS, assumed to be a canonical PDZ interaction,
has indeed consistently evaded elucidation. NOS1AP is the most
prominent nNOS-PDZ ligand in the literature but terminates in
the Class II “IAV” motif (X-COOH) (Vaccaro and Dente,
2002). In contrast, peptide and two-hybrid screens revealed that
nNOS-PDZ binds a distinct “Class III” ligandmotif ending G(D/
E)xV (Schepens et al., 1997; Stricker et al., 1997). A large-scale
systematic analysis revealed only three ligand peptides for nNOS-
PDZ (Stiffler et al., 2007). These were not similar toNOS1AP and
had affinities weaker (15–78 M) than other ligand-PDZ pairs
studied.
Here we report that the C-terminal peptide from NOS1AP
exhibits virtually no affinity for nNOS, and confirm this by mul-
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tiple methods. In contrast, full-length and large C-terminal frag-
ments of NOS1AP interact extremely tightly in conventional
pull-down assay. This was dependent on the PDZ ligandmotif as
deleting the three C-terminal residues eliminated stable binding.
Surprisingly, the PDZ ligand motif was entirely dispensable for
binding in interaction assays without washing steps and for in-
teraction between nNOS and NOS1AP fragments in intact cells.
Our data suggest a heterodivalent interaction between NOS1AP
and the PDZ domain. This involves the following: (1) a previ-
ously unidentified site, which may be the primary interaction, as
it is sufficient alone; and (2) the C-terminal PDZ ligand motif,
which is not sufficient alone but stabilizes binding (4-fold dif-
ference in koff). An alanine scan of an evolutionary conserved
internalmotif identifiedNOS1AP residuesGlu429 and Phe431 as
critical for this second binding site.
This heterodivalent interaction potentially provides two dis-
tinct opportunities for development of drugs to inhibit interac-
tion, whereas targeting both sites might increase selectivity and
reduce off-target effects. As nNOS-NOS1AP interaction contrib-
utes to p38 activation and excitotoxic lesions (Li et al., 2013), we
investigated whether each site alone provides opportunities for
intervention. Cell-permeable peptides (1) based on NOS1AP
containing both sites, (2) possessing the second or “ExF motif”
interaction site but lacking the PDZmotif, or (3) the PDZ ligand
we previously developed (TAT-GESV) each inhibited NMDA-
evoked p38MAPK activation. In organotypic hippocampal slices,
these conferred neuroprotection, which in the case of the internal
motif peptides depended on residues 429/431. In summary, we
showed that NOS1AP interacts with nNOS via two distinct sites,
which cooperate to generate both affinity and stability. This sug-
gests that the heterodivalent form of interaction provides two
alternate avenues for interference with signaling processes and
tissue lesions in disease models.
Materials andMethods
Peptides
ShortpeptideswereobtainedfromGENECUSTorGenicBioasfollows:“EIAV,”
NH2-DSLDDEIAV-COOH; “TAT-GESV,” NH2-GRKKRRQRRR-YAGQ-
WGESV-COOH; and “TAT,”NH2-GRKKRRQRRR-COOH.
Longer peptides were expressed as GST fusions from pGEX6P vectors,
affinity purified on immobilized GSH, and released from the GST by
on-column cleavage with 3C human rhinovirus protease (plasmid
generously provided by Professor John Heath, School of Biosciences,
University of Birmingham, Birmingham, United Kingdom). These
included NOS1AP(400–506), NOS1AP(400–503), NOS1AP(432–
506), and NOS1AP(432–503). TAT-fused NOS1AP peptides used were
expressed with an additional His-tag from pET28a.
Antibodies
Rabbit polyclonal antibodies against CAPON/NOS1AP(R-300), nNOS
(Z-RNN3), and phospho-p38 (“T183/Y185”) were from Santa Cruz Bio-
technology, Invitrogen, and Cell Signaling Technology, respectively.
Rabbit monoclonal against p38 isoforms (clone D13E1) was from Cell
Signaling Technology, and mouse monoclonal against GST (clone B10)
was fromSantaCruzBiotechnology. Secondary reagentswere fromSanta
Cruz Biotechnology, Cell Signaling Technology, and Millipore Biotech.
Cloning, plasmids, and plasmid preparation
Constructs encoding pEGFP and pGEX-human nNOS constructs, hu-
man NOS1AP fused to luciferase, and unfused luciferase vector were
described previously (Li et al., 2013). The construct encoding GST-fused
nNOS 1–155 formammalian expression, pKEBG-nNOS 1–155, was con-
structed by replacing the CMV promoter and GFP coding sequence of
pEGFP-nNOS 1–155 with the EF1 promoter and GST coding sequence
from pEBG. NOS1AP fragments incorporating amino acids 1–503, 382–
506, 400–506, 432–506, 400–503, and 432–503 were generated by PCR-
based methods from full-length human NOS1AP plasmid previously
described (Li et al., 2013). Alanine scan point mutants were obtained by
insertional overlapping PCR in coding sequences for regions 400–503
and 400–506. Fragments were transferred to corresponding vectors to
generate the Luciferase, monomeric Cherry, and GST (pGEX6P) fusion
plasmids for assays as indicated. Constructs encoding PSD95-PDZ2 and
PDZ3 fused to luciferase were generated by transferring the PDZ2 and
PDZ3 sequences to luciferase vectors from corresponding pGEX vectors
previously described (Cao et al., 2005). His tagged nNOS 1–108 and
1–133 were described previously (Tochio et al., 1999, 2000). TAT fusions
were generated from the pET28a vector into which TAT sequence had
been inserted followed by the wild-type or mutant NOS1AP encoding
sequence fragments as indicated.
Recombinant protein preparation
GST-tagged PSD95-PDZ3, Tiam1-PDZ, SCRIB-PDZ4, nNOS(1–155)wt
(“ePDZ”), and Y77H/D78E and free GST were prepared from
BL21(DE3) Escherichia coli strain as described previously (Courtney and
Coffey, 1999). Native and denatured His/TAT-tagged proteins were pre-
pared similarly by immobilized metal-affinity chromatography follow-
ing protocols provided by Steven Dowdy (Becker-Hapak et al., 2001).
Purity and size were checked by SDS-PAGE gels by Coomassie staining.
Cell culture, transfection, NMDA stimulation, cell lysis, and
phospho-p38 detection
Cortical neuron cultures were prepared from P0 rats of either sex
(mixed) as described previously (Semenova et al., 2007). All isolation of
cells and tissues from animals was performed in accordance with corre-
sponding local, national, and European Union regulations. The cells
were cultured in NeurobasalA/B27medium (Invitrogen) and stimulated
with NMDA after exposure to TAT peptides (denatured to enhance cel-
lular uptake and in-cell renaturation, as recommended by Becker-Hapak
et al., 2001) as indicated, to evaluate inhibition of excitotoxic signaling.
Excitotoxic stimulation of cortical neurons (8 DIV) was performed as
described previously (Li et al., 2013). Briefly, neuroprotectant Neuro-
basalA/B27 culturemediumwas replaced withMEM supplemented with
glutamine, penicillin/streptomycin,  peptides 1 h before NMDA as
indicated. Activation of p38MAPK was determined by immunoblotting
of cleared neuron lysates in Laemmli buffer after 10 min of NMDA
treatment.
The 293T andCOS7 cell lines were cultured as previously described (Li
et al., 2013). COS7 cells were transfected with lipofectamine2000 (Invit-
rogen) according to the manufacturer’s protocol, and 293T cells were
transfected with the CaCl2 phosphate method. Transfected cells were
rinsed twice in PBS, lysed by scraping into low salt buffer (LSB) supple-
mented with protease inhibitors and detergent 0.5% Igepal as described
previously (Li et al., 2013). Lysates were cleared by centrifugation at
20,000 g, 4°C for 10 min.
Organotypic hippocampal slice cultures
Organotypic hippocampal slice cultures were prepared according to a
previously described procedurewithmodifications (Kasri et al., 2008). In
brief, 7-day-oldWistar rats of either sex (mixed)were decapitated; brains
were collected in dissection medium (low Na ACSF containing 1 mM
CaCl2, 5 mM MgCl2, 4 mM KCl, 26 mM NaHCO3, 8% sucrose, 0.5%
phenol red, oxygenated with 95% O2/5% CO2 gas mixture in a beaker
chilled on salted ice), and hippocampi were dissected and transversely
sliced into 400-m-thick slices on a McIlwain tissue chopper (Mickle
Laboratory). The slices were transferred to culture medium. Only slices
with an intact structure of CA and DG regions were selected. Four slices
were placed onto each 30 mmMillicell cell culture insert (0.4 m,Milli-
pore), which were placed in 6-well tissue culture plates with 750 l of
filter-sterilized long-term slice culture medium (MEM-Hanks medium,
1 mM L-glutamine, 1 mM CaCl2, 2 mM MgSO4, 1 mg/L insulin, 1 mM
NaHCO3, 20% heat inactivated horse serum, 0.5 mM L-ascorbate, 30 mM
HEPES) under the insert. The slices were placed in a humidified chamber
with 5% CO2 at 35°C, and medium was exchanged every second day.
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Protein interaction assays
Pull-down assays: conventional, no wash, and filter-plate assays
Conventional pull-down assay. These were performed as previously de-
scribed by incubating immobilized recombinant GST fusion proteins (2
g/assay) as indicated with cleared lysates of 293T cells expressing solu-
ble protein as shown in the figures (pLuc-C1 vector expressing only
firefly luciferase used as a negative control). To assist with quantification,
the expressed soluble proteins were expressed as fusions with firefly lu-
ciferase as described previously (Li et al., 2013). Beadswere rotated for 1 h
at 4°C to allow binding, and beads were washed three times and resus-
pended in CCLR (Promega) before quantification using luciferase assay
reagent. Total “input” amount used in each case was normalized (7000
units per assay of 250 l, using a Turner TD20/20 10 s measurement).
The final amount in the bead pellet was also measured, and pull-down
data were expressed as percentage of total.
No-wash assays using purified recombinant proteins. To identify inter-
acting protein that is lost during the washing steps in a conventional
pull-down assay, and avoid possible contributions of other proteins in
cell lysates, some experiments were performed with purified recombi-
nant GST-nNOS immobilized on glutathione beads and purified
NOS1AP fragments cleaved off from the GST moiety in an on-bead
cleavage protocol using GST-rhinovirus 3C protease. Purity was vali-
dated by observing a single band on a Coomassie-stained gel. We used
residues 1–155 of nNOS as this encompasses the extended PDZ domain,
including the flanking -finger motif, and a recombinant of this length
was more readily produced than shorter fragments.
Filter-plate assay. Alanine scan pulldown: To each well of a 96 well
U-bottom plate, 2 l beads bound to 1 g GST or GST-fused nNOS
protein as indicated were dispensed. Cell lysates containing equal
amounts of luciferase fusion proteins were added to each well to a final
volume of 100 l per well. Beads were incubated 60 min at 4°C with
gentle shaking and transferred to a multiscreen filter plate (Millipore),
cell lysate removed by applying vacuum 30 s. Once pressure had normal-
ized, beads were resuspended in lysis reagent. The 96 channel pipetting
and vacuum control were performed with a Biomek NXP96 (Beckman-
Coulter). Luciferase assay reagent was added and signalmeasured using a
plate reader (Polarstar, BMG). TAT peptide affinity assay: 5 l beads
bound to 1 g GST-fused nNOS protein (or GST for background mea-
surement) were rotated with concentrations of native recombinant His-
TAT-NOS1AP peptides as shown for 1 h at 4°C and transferred to
multiscreen filter plates (Millipore). Unbound peptideswere removed by
centrifuging at 1000 g for 5 min. Beads were resuspended in LSB and
protein eluted with 4 Laemmli buffer, boiling at 95°C for 10 min. The
affinity of each peptide was determined using fluorescent immunoblot-
ting, with DyLight 680-conjugated anti-rabbit secondary antibody (Cell
Signaling Technology), quantified with the Odyssey infrared imaging
system (LI-COR) and ImageJ as follows. Bound peptide, together with
the background binding of each TAT peptide to GST beads, was quanti-
fied in each blot using a set of standard concentrations of the same TAT
fragment on the same blot. Background binding, barely detected, except
at the highest fragment concentration, was subtracted in each case. Fit-
ting was performed for each replicate with Excel using the quadratic
solution formula to account for bound ligand, fbB/L0 {(KdP0
L0) [(Kd  P0  L0) ˆ 2  4L0P0]}/2L0. The affinities of His-TAT-
NOS1AP[400–503] Ala-mutant peptides were so weak that their Bmax
could not be directly obtained and the Bmax of His-TAT-NOS1AP[400–
503] wild-type peptide was assumed to be applicable also to the mutants
to estimate their Kd values. Even if this assumption is not correct, it is
clear from the results (see Fig. 9C) that the mutants bind extremely
weakly.
Bead-immobilized protein perfusion and semiquantitative
kinetic analysis
GST-tagged nNOS 1–155 was prepared as described by affinity chroma-
tography on glutathione agarose beads. A perfusion chamber was devel-
oped using a Parafilm spacer (nominal thickness 0.127mm) into which a
rectangular trough was cut, between a glass slide substrate and 25-mm-
diameter glass coverslip upper window. A 1 ml pipette tip, beveled at the
open end, was attached with Parafilm as the in-port of the perfusion
chamber. The chamber was heated to allow the Parafilm tomelt and seal.
The in-portwas further sealedwith nail varnish and allowed to dry. Beads
were applied from the out-port, driven in by surface tension, and trapped
in the chamber. Buffer was allowed to flow-through the in-port past the
beads by gravity flow at 0.3 ml/min and effluent leaving the out port
removed by open aspiration. NOS1AP 400–503 and 400–506 were
affinity-purified as GST-tagged fusions, cleaved on beads with GST-
tagged 3C-HRV protease, and labeled with FITC (Sigma) according to
standard protocols (Invitrogen). Proteins labeled at low stoichiometry
(0.1–0.2 dyemolecules per protein, byOD494/280)were purified from
FITC label and desalted by spin column (Bio-Rad Biospin P6), normal-
ized for label by addition of unlabeled protein, and diluted in buffer to
normalize protein levels. Labeled protein (50 l at 10 M) was intro-
duced into a sample loop in the gravity flowpath and allowed to flowover
the beads followed by buffer without protein at a continuous rate (0.3
ml/min). Beads were imaged using a fluorescent microscope (IX70 with
10N.A.0.3 objective, XLED1 460 nm excitation, 510 nm LP emission
filter) with a Hamamatsu Flash4 CMOS camera (500ms exposure, 4 4
binning) using HCimage camera software. Data from bead ROIs were
corrected using neighboring background ROIs, subtracting contribution
from buffer in the bead ROIs (beads are approximately spherical,
whereas ROIs represent cylindrical volumes) and a term representing
systemdark value and aminor exponential background drift (in the form
A0[1-e
kt] where k 0.0013 s1 in all cases). Residual bead fluorescence
(see Fig. 5A, top) remains but appears relatively constant and therefore
will not contribute to decay curves. Decay curves were fitted to the
Schuck and Minton two-compartment model for dissociation under
flow conditions (Schuck and Minton, 1996; de Mol and Fischer, 2008).
This model includes terms to correct for rebinding of released protein.
We assumed that the fluorescein dye does not bleach during the imaging
time, but this does not affect the observation that 400–506 remains on
beads considerably longer and a difference in off-rate is the most likely
explanation.
Solution methods
Protein peptide ligand interaction assay by fluorescence polarization. Fluo-
rescence polarization assays were performed using a PerkinElmer Life
Sciences LS-55 fluorimeter equipped with an automated polarizer (see
Fig. 1) or a BMG Polarstar OPTIMA reader (see Fig. 5) set at 25°C in all
cases. Synthetic peptide corresponding to the C terminus of NOS1AP
(residues 400–506) or nonamer peptides “-EIAV” was labeled with
fluorescein-5-isothiocyanate (Molecular Probes) at the N terminus and
purified by passing the reaction mixture through a Superdex200 or Su-
perdex Peptide column (GE Healthcare) according to size. In the case of
-EIAV (see Fig. 2), fluorescence titration was performed by adding in-
creasing amounts of His-Tagged nNOS core PDZ domain (1–108) to a
constant amount of the fluoresceinated peptide (1 M) in 50 mM Tris
buffer, pH 7.4, containing 100 mM NaCl, 1 mM EDTA, and 1 mM dithio-
threitol. The dissociation constant (Kd) was obtained by fitting the titra-
tion curves with the classical one-site binding model 	mP  mPmax *
[nNOS]/(Kd [nNOS]) using the softwareGraphPad Prism (GraphPad). Ex-
periments were performed in triplicate. In the case of NOS1AP[400–506]
peptide (used at 50 nM) nNOS (1–155) cleaved from a GST fusion was
used for titration to be consistentwith the bead-based assays in preceding
figures. The same buffer as above was used. Fitting was performed with
Excel using the quadratic solution formula to account for bound ligand,
fb B/L0 {(Kd P0 L0)[(Kd P0 L0) ˆ 2 4L0P0]}/2L0.
	mP is calculated frommPmP0, where mP is the measured polariza-
tion value of each titration point andmP0 is the polarization value of the
free peptide.
Isothermal titration calorimetry (ITC). ITC measurements were per-
formed on a VP-ITC calorimeter (Microcal) at 25°C. All protein and
peptide samples were in 20 mM, pH 7.0 Tris-HCl buffer. The titration
processes were performed by injecting 10 l aliquots of the nNOS ex-
tended PDZ (1–133) fragments into untagged NOS1AP 9-mer peptide
-EIAV at time intervals of 3min to ensure that the titration peak returned
to the baseline. The titration data were analyzed using the program Ori-
gin 7.0 from Microcal and fitted using the one-site binding model.
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Coprecipitation methods
Coimmunoprecipitation of luciferase fusion proteins coexpressed with
GFP fusion proteins was performed as previously described (Li et al.,
2013). Precleared HEK-293T lysates cotransfected with pEGFP-nNOS
full-length and pLuc-NOS1AP full-length (pEGFP-C1 and pLuc-C1 as
controls) in LSB/protease inhibitors and 0.5% Igepal detergent were co-
immunoprecipitated by rotation 1 h at 4°C with 5l of beads coupled to
a single-chain anti-GFP camelid antibody-based protein (“GFP-Trap,”
Chromotek). Beads were washed 3 times in LSB/protease inhibitors and
0.5% Igepal detergent, drained beads resuspended in cell culture lysis
reagent (Promega), and luciferase in washed bead and input samples
were measured and precipitated activity was normalized to initial levels
for each sample.
Coprecipitation of luciferase-fused NOS1AP mutants coexpressed
with GST-fused nNOS[1–155] was performed similarly, except that glu-
tathione Sepharose 4B (GE Healthcare) beads were used to precipitate
the nNOS. Efficiencies of precipitation were measured by immunoblot-
ting with anti-GST (scbt clone B14) and coprecipitation by luciferase
assay as above.
Imaging and segmentation of COS7 cells for protein
interaction assay
Transfected COS7 cultures were incubated with Hoechst (1 g/ml, 15
min in 37°C before imaging) to facilitate algorithm-based image segmen-
tation. The cultures were imaged (20 NA 0.45 long-working distance
objective, laser-based focus, 4 4 fields captured per well) with filter sets
to obtain Hoechst, YFPVenus and Cherry images. Data were analyzed
with the aid of AttoVision1.7 software (BDBiosciences) using automated
background correction (constant value) of each channel followed by
segmentation as follows:
Hoechst images were used to seed polygons (preprocessing parame-
ters: median 5 5, rolling ball 25 25, dilate 3 3, automated thresh-
olding level 1, size range 250–3000) eroded by 6 pixels to define nuclear
regions of interest without potential contamination from cytoplasmic
signals. The uneroded polygons were expanded using corresponding
Cherry images (preprocessing: median 5  5, automated thresholding
level 2) to define cytoplasmic regions. Dilation was limited to 10 pixels to
ensure the cytoplasmic regions belonged to the corresponding nuclei and
not neighboring cells, and erosion 1 pixel to increase discrimination from
corresponding nuclear ROIs. Untransfected cells (intensity of cytoplas-
mic region in Cherry channel 
 threshold value of 100) were excluded
from analysis. The translocation index was defined for each cell as the
ratio of YFP channel average pixel intensity in cytoplasmic regions to the
corresponding nuclear regions of the same cell. For each well, an average
of the ratio of all transfected cells (mean 40 4 per well) was obtained,
and the data were graphed asmean SEMof well averages (n 3 wells).
Protein structure visualization and prediction and
evolutionary conservation analysis
Protein structure data presentations were rendered with UCSF-Chimera
and POVray (Pettersen et al., 2004). Evolutionary conservation analysis
was performed using the Consurf server (Ashkenazy et al., 2010). Sec-
ondary structure prediction tools used were JPRED (Cole et al., 2008)
and PSIPRED (Buchan et al., 2013).
Excitotoxic stimulation and imaging of slice cultures for
tissue lesion assay
Following the protocol of Bunk et al. (2010), at 8–10 d in vitro, cultured
slices were selected by propidium iodide staining (2 g/ml for 15 min in
conditionedmedium) to exclude damaged cultures. Slices were rinsed in
experimental buffer containing 120 mM NaCl, 3.5 mM KCl, 0.4 mM
KH2PO4, 5 mM NaHCO3, 20 mM HEPES, and 1.2 mM Na2SO4 supple-
mented with 15 mM glucose and 1.2 mM CaCl2, and exposed to 50 M
NMDA for 30 min at 35°C in the same medium. Control slices were
treated with experimental buffer alone. After treatment, the slices were
washed in the same buffer (without NMDA) and conditioned medium
was added. Slices were analyzed for propidium iodide staining after 24 h.
Images were acquired with a BD pathway 855 imager (2.5 objective,
555 nm/28 nm excitation, 595 nmLP dichroic, 645 nm/75 nm emission).
Quantification of cell death in slice culture images
This was performed as described previously (Bunk et al., 2010; D’Orsi et
al., 2012). Briefly, fluorescence of propidium iodide staining in CA1,
CA3, and DG subfields (three 0.027 mm2 areas per subfield measured
and averaged) of the slices (4–8/condition) were quantified from images
taken 24 h after addition of NMDA using ImageJ software. For each
image, background fluorescence was calculated similarly from image re-
gions from the filter support neighboring the slice. This signal was sub-
tracted from each subfield value. One-way ANOVA was performed
followed by Newman-Keuls Multiple Comparison Post Hoc Test. p 

0.05 was considered significant.
Confocal imaging of COS7 cells for protein localization
COS7 cells were imaged through a 40 NA 1.3 objective (Nikon) on a
Diaphot configured with a Biorad Radiance 2100 laser confocal scanner.
GFP fusions were imaged with the 488 nm argon laser line for excitation,
a 515/30 emission filter, and a multialkali cathode photomultiplier.
Cherry fusions were imaged with the 543 nm HeNe laser line for excita-
tion, a 600LP emission filter, and a gallium-arsenide phosphide photo-
multiplier. Laser intensities and gain settings were adjusted to avoid
saturation of the detectors (typically 1%–10% for the 488 nm line and
100% for the HeNe line). xy images of dimension 324 256 pixels were
obtained with 0.38 m interval. xz images on the line showed in the
figureswere obtainedwith 0.5minterval over a z range of 25m.Green
and red images were merged with ImageJ; and when both red and green
proteins were present, the image contrasts were linearly adjusted so that
both red and green (yellow when overlapping) were clearly visible in the
merged images.
Statistical analysis
Data were analyzed by one- or two-way ANOVA followed by Newman-
Keuls Multiple Comparison Post Hoc Test.
Results
The isolated PDZmotif of NOS1AP does not interact with
nNOS but contributes to binding in a pull-down assay
The binding of NOS1AP to nNOS has been suggested as potential
target for development of therapeutic agents in some of the most
common causes of death and disability (Li et al., 2013;Weber et al.,
2014; Zhu et al., 2014). NMR structure analysis showed that nNOS-
PDZ forms a canonical PDZ interactionwithMelR peptide (Tochio
et al., 1999) (Fig. 1A), andNOS1APwas also thought to interactwith
nNOS in thisway (Jaffrey et al., 1998; Tochio et al., 1999).Canonical
PDZ interactions involve the docking of a shortmotif, typically 4 or
5C-terminal amino acids, into the binding pocket of a PDZdomain
(Doyle et al., 1996;Harris andLim, 2001). Surprisingly, however,we
found the affinity of the nNOS-PDZ domain for the C-terminal
peptide fromNOS1APwasexceedingly low(“-EIAV,”Kd600M,
Fig. 1B). An independent method, ITC, was applied to this peptide,
givinga similar estimateofKd (datanot shown).Notably, this levelof
affinity is consistent with a recent report that found it necessary to
use50–500nmolof a12aminoacidC-terminalNOS1APpeptideby
intrahippocampal injection to disrupt nNOS-NOS1AP interactions
(Zhu et al., 2014). This approximates to 2–20mMpeptide, asmouse
hippocampus has a total volume25l (Persson et al., 2014).
Such a low affinity is not considered significant binding. The
NOS1APC terminus conforms to aClass IImotif, and yet nNOS is a
Class III PDZ domain (Vaccaro and Dente, 2002). We asked
whether the PDZ classmismatchwas responsible for theweak inter-
action observed. NOS1AP-nNOS interaction has been reported in
pull-down assays (Jaffrey et al., 1998). Therefore, we used a panel of
recombinant immobilizedPDZdomainsofdifferent classes forpull-
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down assays (Fig. 1C). Full-length luciferase-tagged NOS1AP was
recovered from cell lysates by the extended nNOS-PDZdomain im-
mobilized on beads (Fig. 1D). Recovery was extremely efficient, 10-
fold better than obtained with the well-established PDZ domain
interaction between PSD95-PDZ2 and nNOS -finger (Fig. 1E)
(Hillier et al., 1999; Christopherson et al., 1999; Tochio et al., 2000).
Pull-down of NOS1AP with nNOS is dependent on the last three
amino acids ofNOS1AP, Ile-Ala-Val, as a construct lacking thismo-
tif (“	IAV”) was not recovered in the pull-down (Fig. 1D). This is a
characteristicpropertyofPDZ interactions.We find that thisClass II
PDZmotif (X type) (Vaccaro and Dente, 2002) did not mediate
binding of NOS1AP to the Class II PDZ domain tested (from
Tiam1), whereas the Class I PDZ domain (from PSD95) did not
bind detectably under any conditions tested. Scrib-PDZ4 is of un-
known specificity (Zhang et al., 2006) but was included as it is re-
ported to interact with NOS1AP PTB domain (Richier et al., 2010).
However, we do not observe an interaction in this assay.
Thus full-length NOS1AP forms a stable complex with the
extended PDZ domain in nNOS in a manner dependent on the 3
C-terminal residues (Fig. 1D). However, the interaction was not
detectable by conventional solution interaction assays using the
PDZ domain and the 9 residue C-terminal peptide (Fig. 1B). We
next investigated this discrepancy with series of pull-down assays
using NOS1AP fragments.
Mutation of key residues in the nNOS-PDZ pocket reduces
pull-down of NOS1AP
Mutating critical residues in the PDZ ligand-binding pocket to cor-
responding residues in a Class I PDZ domain (PSD95-PDZ3)
strongly reduced binding to the nNOS extended PDZ domain (1–
155) but did not eliminate it (WT vs Y77H/D78E; Fig. 2A). This is a
subtlemutation, not expected to eliminatePDZ functionbutmerely
change its selectivity (Stricker et al., 1997; Christopherson et al.,
1999). The results suggest that NOS1AP does interact with the PDZ
domain ligand-binding pocket, as expected for a canonical PDZ in-
teraction (Fig. 1A). Contradicting the assumption of a canonical
interaction, however, we found the C-terminal motif of NOS1AP
(“-EIAV”) showednobindingwhetherwild-typeorClass I-likemu-
tant domain is used (Fig. 2A). This result is consistent with lack of
bindingof this sequence as an isolatedpeptide in fluorescencepolar-
izationor ITC (Fig. 1B; anddata not shown). This suggests the bind-
ing is indeed not a canonical PDZ interaction after all.
We have found that nNOS and NOS1AP can form a very
stable complex compared with related interactions, such as
that between nNOS and PSD95PDZ2, in cell-free assays using
exogenous immobilized nNOS fragments (Fig. 1D,E). To
consider intact full-length proteins, we coexpressed con-
structs for full-length nNOS and NOS1AP in 293T cells. Im-
munoprecipitation of nNOS from lysates coprecipitated
Figure 1. NOS1AP C terminus does not bind nNOS, but the full-length protein binds strongly. A, Projection of MelR 9-mer peptide docking in the ligand-binding pocket of nNOS-PDZ, a canonical
PDZ interaction (1B8Q.pdb NMR structure 1, Tochio et al., 1999; projected with Chimaera, Pettersen et al., 2004).B, The fluoresceinated C-terminal PDZmotif of NOS1AP/Capon (DSLDDEIAV) binds
with nNOS (His-tagged residues 1–108) in fluorescence polarization assay at an affinity, determined by curve fitting, of600M. This method provides17M affinity for Cx43 9mer ligand
binding ZO1-PDZ2, for example (Chen et al., 2008). C, D, GST-fused domains of different PDZ classes (shown in Coomassie gel) were used for pull-down assay (2 g immobilized PDZ/assay,
pull-down expressed as percentage of input as described in Materials and Methods), revealing efficient recovery of NOS1AP by nNOS-extended PDZ. This requires the C-terminal Class II-type PDZ
ligandmotif “IAV” because an equal amount of NOS1AP-	IAV, in which the motif is deleted, is not pulled down. The motif does not mediate binding to the Class II PDZ domain, whereas the Class
I PDZ domain like Scrib-PDZ4does not bind detectably. The Class II PDZ domain does bind toNOS1AP, but this binding persists even in the absence of the Class IImotif. ***p
 0.001 (Newman-Keuls
Multiple Comparison Post Hoc Test after ANOVA). ns, Not significant. E, The efficiency of the well-characterized interaction between nNOS-finger (distinct from but adjacent to the PDZ binding
pocket) and PSD95-PDZ2 is shown for comparison.
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10% of total NOS1AP expressed, suggesting that these pro-
teins also form stable complexes in intact cells (Fig. 2B). xz
scans of COS7 cells expressing full-length NOS1AP alone (Fig.
2C, red) showed that it localizes to the plasma membrane,
whereas full-length nNOS alone does not (Fig. 2D, left, green).
Coexpression of both (Fig. 2D, right, lower cell) showed that
the presence of NOS1AP relocalizes nNOS to the plasma
membrane. This suggests that these proteins interact quanti-
tatively in intact cells.
NOS1AP residues between 400 and 431 are required for
interaction with nNOS
Full-length NOS1AP exhibits substantial binding to nNOS,
but the C-terminal PDZ ligand motif alone does not bind
(Figs. 1B, 2A). We performed progressively larger N-terminal
deletions to map the binding requirements. Stable interaction
was retained until NOS1AP residues 400–431 were removed,
which resulted in precipitous loss of signal (Fig. 3A). The
requirement for both region 400–431 and C-terminal motif
(amino acids 504–506) for stable binding in pull-down (Figs.
1D, 3A) suggests one of three scenarios: (1) region 400–431
contributes to binding nNOS indirectly via undefined compo-
nents in lysates of cells expressing NOS1AP fragments (Fig.
3Bi); (2) 400–431 is required for correct folding and presen-
tation of the PDZ ligandmotif 504–506 (Fig. 3Bii), like the salt
bridge between residues Asp62 and Gln121 in nNOS is re-
quired for a correctly presented -finger (Tochio et al., 2000;
Karlsson et al., 2012); or (3) 400–431 contributes a second,
previously unidentified, contact with the nNOS-PDZ domain
that is critical for interaction (Fig. 3Biii).
nNOS-NOS1AP interaction occurs independent of other
cell components
To address the first scenario (i.e., that undefined components
from 293T lysates used in pull-downs mediate the interaction),
we generated recombinant immobilized GST-nNOS[1–155] and
NOS1AP[400–506] purified to homogeneity (by Coomassie, Fig.
4A) after proteolytically removing the GST tag. NOS1AP[400–
506] formed stable interactions with immobilized nNOS[1–155]
and was efficiently retained on washed beads (Fig. 4Bi), whereas
NOS1AP[400–503] was almost completely lost even though 20-
foldmore nNOSwas used comparedwith Figures 1, 2, and 3. This
indicates that NOS1AP[400–506] exhibits stable binding to
nNOS[1–155] on beads in the absence of other detectable pro-
teins, dependent on residues 504–506.
Figure 2. The PDZ ligand-binding pocket of nNOS and the 3 C-terminal PDZ motif residues (IAV) are necessary for NOS1AP-nNOS interaction, but the PDZ motif is not sufficient. A, GST-nNOS
residues 1–155 were bead-immobilized and exhibit efficient pull-down of full-length NOS1AP, but not the NOS1AP PDZ motif (9 C-terminal amino acids ending EIAV). The previously described
ligand-binding pocket double-mutant Y77H/D78E (see text) exhibits reduced binding to full-length NOS1AP. GST and empty vectors were used as negative controls. Recombinant proteins used are
shown in the Coomassie gel under the histogram. ***p
 0.001 (Newman-KeulsMultiple Comparison Post Hoc Test after two-way ANOVA). ns, Not significant.B, The 293T cells were cotransfected
with constructs for full-length NOS1AP (luciferase fused for quantification) and nNOS (EGFP-fused to facilitate affinity purification). Cell lysates were incubated with GFP-binding protein beads to
immobilize the nNOS, and pulled down using a conventional protocol (see Materials and Methods). The coexpressed NOS1AP was efficiently copurified while controls produced negligible signal.
***p
 0.001. C, COS7 cells were transfectedwith plasmid encoding Cherry-fused NOS1AP and untargeted EGFP expression vector, and imaged by laser scanning confocalmicroscopy in xy (bottom
panel, merged images) and xz planes (top, image channels andmerged channels as shown), taken at the thickest part of the cell to facilitate visualization of membrane localization. The white line
on the xy image indicates the location of the xzplane scanned (125mwidth 25mdepth). NOS1AP localizes to the edges of the cell, presumably near or at the plasmamembrane.D, COS7 cells
were transfectedwith full-length fusion constructs encoding Cherry-NOS1AP and EGFP-nNOS as indicated, and imaged by laser scanning confocalmicroscopy in xy (bottompanels, merged images)
and xz scans (top, image channels andmerged channels as shown) as inC. Alone, nNOS resides predominantly in the cytoplasmand is excluded from thenucleus and vesicular structures (left panels).
However,when coexpressedwithNOS1AP,nNOS translocates toNOS1AP (rightpanels) atmembraneproximal regions, and thenegative contrastwith thenucleus andvesicular structures is lost. This
suggests that the expressed proteins interact to a substantial extent in intact cells.
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Residues 504–506 are dispensable for interaction but
required for stable retention on nNOS beads
NOS1AP was greatly depleted from the supernatant even in the
case of NOS1AP[400–503] (Fig. 4Bii), suggesting that binding
indeed occurred but was lost during washing steps. Conventional
pull-downassays require both affinity and slowoff-rates so that cap-
tured protein is not lost during washes. Off-rates for signaling mol-
ecule interactions vary widely. Thus complexes of Ras with Nore1
have100-fold longer lifetimes thanRas-Raf complexes (Avruch et
al., 2009), whereas moderate-affinity interactions may be barely de-
tected if they are very transient. We modified the procedure to re-
move supernatant from beads by rapid centrifugation through a
filter without washing steps (Fig. 4C). This revealed that even [400–
503] exhibited substantial binding,which is lost in subsequentwash-
ing steps (Fig. 4Dii), as we suspected. In contrast, peptides lacking
residues 400–431 were not retained even in drained unwashed
beads (Fig. 4Diii–Div).
These results with purified proteins indicate the following: (1)
nNOS[1–155] can bind NOS1AP[400–506] directly, in the ab-
sence of cellular proteins (Fig. 4Bi); and (2) PDZ motif residues
504–506 are not obligatory for binding but are required for a
stable interaction (Fig. 4Di,Dii). This suggests the canonical PDZ
interaction (C-terminal residues docking in the PDZ domain
pocket) (Doyle et al., 1996) is dispensable for nNOS:NOS1AP
protein complex to form. However, it does provide a secondary
contribution to the interaction, enhancing lifetime of the com-
plex. Short-lived complexes are revealed as such upon washing.
Consistent with this, all pull-down experiments using washing
steps show no binding when the PDZmotif, residues 504–506, is
absent. The data do not support a role for NOS1AP residues
400–431 in merely maintaining conformation of the C-terminal
PDZmotif 504–506 for PDZ binding (Fig. 3Bii) as the motif can
be removed without eliminating binding, unlike residues 400–
431 (Fig. 4D). Instead, a previously uncharacterized nNOS inter-
action site overlapping with NOS1AP region 400–431 appears
critical for interaction affinity. The PDZ motif merely increases
stability of the nNOS:NOS1AP complex. In conclusion, maximal
stable binding of NOS1APwith the nNOS-PDZ domain depends
on a heterodivalent interaction.
To directly visualize in real time whether release of
NOS1AP from nNOS depends on the PDZ motif as inferred
above, we established a system in which nNOS protein beads
used in Figures 123-4 are trapped in a perfusion chamber. We
applied FITC-labeled NOS1AP fragments and monitored loss
of fluorescence under buffer flow (Fig. 5A; see Materials and
Methods). The curves obtained clearly show that deletion of
the PDZ motif substantially reduces the apparent rate of loss
of label from nNOS beads (Fig. 5B). We applied the Schuck
and Minton two-compartment model for dissociation under
flow conditions (which takes account of rebinding) (Schuck
andMinton, 1996; deMol and Fischer, 2008), which fitted well
to the decay phases of the data (Fig. 5Ci–Civ). Both fitted curves
have on-rates5M1 s1, consistent with a previously described
PDZmotif interaction(Chiet al., 2009).However, the fittedoff-rates
are extremely low.NOS1AP[400–506] shows an4-fold lower off-
rate and therefore a corresponding higher apparent affinity (Fig.
5Cv). As solid-phase assayswithGST fusions canoverestimate affin-
ities, wemeasured affinity by fluorescence polarization after proteo-
Figure 3. Binding of NOS1AP to nNOS beads requires residues 400 – 431 but not residues preceding 400. A, N-terminal deletion mutants of NOS1AP as shown were used as luciferase
fusions in a pull-down assay as in Figures 1 and 2 with 2 g immobilized GST-fused nNOS 1–155 or immobilized GST alone as negative control. NOS1AP pull-down is maintained at a
similar level to measurements with full length (Figs. 1, 2) even when residues 1–399 are deleted, but deleting residues 400 – 431 almost eliminates pull-down (n 3; one-way ANOVA,
Newman-Keuls Multiple Comparison Post Hoc Test). ***p 
 0.001. ns, Not significant. B, Three models are proposed to explain the role of NOS1AP residues 400 – 431 in the
nNOS-NOS1AP interaction: (1) Model 1 proposes that an additional protein present in the cell lysate used as a source of NOS1AP in the pull-down experiments serves as a required
interaction platform, with both nNOS and NOS1AP residues 400 – 431 docking with the platform such that both the PDZ motif between nNOS and NOS1AP as well as the platform
interaction are required for stable interaction and thus efficient pull-down; (2) Model 2 proposes that residues 400 – 431 are required for the NOS1AP C-terminal PDZ ligandmotif to adopt
the appropriate conformation to dock effectively in the nNOS ligand-binding pocket; and (3) Model 3 proposes that nNOS possesses two distinct interaction sites; one is the ligand-binding
pocket that forms a conventional PDZ interaction that is by itself extremely weak (affinity1 mM as in Fig. 1) but is complemented by a distinct interaction involving NOS1AP residues
400 – 431 such that both together are required to form a stable interaction and efficient pull-down.
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lytically removing GST tags. This indicated Kd 50 nM (Fig. 5D),
lower affinity than in the perfused bead assay, but still 104 fold
higher than the affinity of theNOS1AP9 residueC-terminal peptide
(Fig. 1B).
Residues 504–506 are dispensable for interaction of NOS1AP
with nNOS in intact cells
Pull-down assays typically include washing steps to mini-
mize background binding. This experimental manipulation
has no direct counterpart in living cells; nevertheless, lifetimes
of protein complexes may greatly impact signaling. If
NOS1AP[400–503] binds and dissociates rapidly, leading to
loss of binding under washing conditions, then in intact cells
we should expect an interaction with nNOS without a strong
dependency on the PDZ motif, even though this would be
counterintuitive based on current literature. Thus, we predict
that NOS1AP[400–503] interacts with nNOS in intact cells.
We expressed in COS7 cells Cherry-fused NOS1AP[400–506],
which was retained in the cytoplasm (Fig. 6Ai,Bi), or EGFP-
fused nNOS[1–155], which diffused to both cytoplasmic and
nuclear compartments (Fig. 6Av,Bii) like unfused EGFP and
Cherry moieties alone (Fig. 6Aii,Aiv). The presence of
NOS1AP[400–506] resulted in relocalization of coexpressed
nNOS to the cytoplasm (Fig. 6Aviii,Biii), whereas [432–506]
or [432–503], which showed no interaction in cell-free assays
(Figs. 3A, 4D), failed to relocalize nNOS (Fig. 6Axiv,Biv,Cv).
Notably, NOS1AP[400–503] also relocalized nNOS to the cy-
toplasm (Fig. 6Axi), although the interaction it forms in a
purified system is detected only when the complexes are not
washed (Fig. 4). This suggests that the NOS1AP-nNOS inter-
action in intact cells does not require the PDZmotif even though the
lifetimeof the complexmaybe affected by thismotif (Figs. 4, 5).
Residues E429/F431 are required for PDZmotif independent
NOS1AP interaction with nNOS in intact cells
The results above suggest that a region within NOS1AP 400–431
is required to form a second contact with nNOS (Fig. 6Axii,Biii).
Evolutionary conservation analysis of NOS1AP[400–506] re-
veals three conservation hotspots: the C-terminal PDZ ligand
motif, a central region, and residues 420–430 (Fig. 7A), the
latter of which secondary structure prediction algorithms sug-
gests may form a -strand (data not shown). To determine the
contributions of residues 421–431 to NOS1AP/nNOS interac-
tion, we applied an alanine scan approach in which consecutive
residues were replaced by alanine (Fig. 7B). A pull-down using
this panel of NOS1AP[400–506] mutants revealed that E429 and
Figure 4. NOS1AP residues 400–431arenecessary for interaction,whereasPDZmotif residues 504–506arenot required for interactionbut stabilize the complex.A, RecombinantGST-nNOSand tag-free
NOS1AP 400–506, 400–503, 432–506, and 432–503 purified to near homogeneity, are shown by Coomassie staining. B, GST-nNOS was immobilized on beads in a conventional pull-down with tag-free
NOS1AP. Input samples, unbound supernatant, andwashedbeadswere probed forNOS1APbyWestern blottingwith a polyclonal antibodyR300 raised against the C-terminal region ofNOS1AP. Using 40g
immobilized nNOS/sample, recovery of NOS1AP 400–506 was quantitative (Bi), but barely detectable with NOS1AP 400–503 (Bii). However, 400–503 was greatly sequestered from supernatant when
exposed tonNOSbeads (middle lanesweaker than inputs). Equal amountsofGST control beads (Biii,Biv) didnot sequesterprotein fromsupernatants (signals inmiddle lanes similar to inputs). Representative
blots are shown (n 3). C, Modification of the pull-down assay to separate flow-through and drained beads is shown schematically. Unbound “supernatant” is separated from beads by spinning through a
spin-filter, providing flow-through samples anddrainedbeads,which canbe resuspendedand rundirectly (“drainedbeads”) orwashed ina conventionalmanner.D, Results of themodifiedbindingassayas in
C are shown. NOS1AP 400–506 is completely depleted from flow-through, and washing beads does not appreciably remove bound protein. In contrast, 400–503 is detected in drained beads but almost
completely lost fromwashedbeads. NOS1APproteins lacking residues 400–432 are not retained ondrained beads to any detectable extent. Representative blots are shown (n 3).
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F431 were most critical for interaction (Fig. 7C). We used the
same alanine scan panel with the in-cell interaction assay of Fig-
ure 6, but with NOS1AP[400–503] because deleting the PDZ
ligand motif removes any ambiguity about its involvement and
ensures maximal dependence of interaction on the region 400–
431 (Fig. 3B). This revealed NOS1AP-induced translocation of
nNOS was most compromised by mutation of residue E429 or
F431 (Fig. 7D) or double mutation of K427/L428. This finding
was further confirmed by performing an independent coprecipi-
tation experiment of NOS1AP alanine mutants with coexpressed
nNOS[1–155] (Fig. 7E). It is notable that amino acids K427,
L428, E429, and F431 are particularly highly conserved residues
throughout evolution (Fig. 8). Thus, whether the PDZmotif (res-
idues 504–506) is present or not, mutating residues E429 or F431
reduces the interaction with nNOS, indicating a requirement for
these side chains independent of the PDZ motif. We refer to this
second interaction site as the ExF motif.
TAT peptides fused to PDZ ligandmotif or ExFmotif
containing region each inhibit excitotoxic activation of
p38MAPK
Our data from cell-free and heterologous systems suggest nNOS:
NOS1AP interaction requires a novel interface between nNOS
and a cluster of residues around and including NOS1AP 429/
431, together with a PDZ ligand that stabilizes the interaction but
alone has virtually no affinity. Nevertheless, loss of the PDZmotif
does destabilize the interaction; and, as previously reported (Li et
al., 2013), competition at this site alone with a synthetic ligand
(TAT-GESV) is sufficient to inhibitNMDA-induced recruitment
of NOS1AP to nNOS and downstream signaling in cultured cor-
tical neurons. This suggests that, in intact cells, a productive
signaling interaction, in the latter case sufficient to evoke ex-
citotoxic pathways, requires the stability of the heterodivalent
interaction conferred by the PDZ ligand motif. We therefore
predicted that competition at the ExF motif would also inhibit
signaling, and simultaneous competition at both sites might
be at least as neuroprotective as either alone. We stimulated
cortical neurons with NMDA after exposure to recombinant
cell-permeable TAT peptides comprising NOS1AP residues
400–503, which lacks the PDZ ligand motif but includes the
ExF containing region, or residues 400–506, which contains
both PDZ ligand motif and the ExF motif. Both recombinant
peptides (with PDZ motif present or deleted) were able to
inhibit NMDA-evoked activation of p38 at least as much as the
PDZ ligand TAT-GESV, which was used as a positive control
for inhibition (Li et al., 2013) (Fig. 9A,B).
Figure 5. Visualization of NOS1AP 400–503/506 binding and Kd estimates by fluorescent methods. A, Beads bound to GST-nNOS1–155 as used in previous figures were trapped in a flow
chamber, an aliquot of fluoresceinatedNOS1AP applied as indicated (middle panel), followed by perfusion of beadswith buffer (bottom). Fluorescent images using a fluorescein filter set are shown.
B, The background region-corrected intensity of fluorescence from the bead, indicating the level of interacting protein, is shown as pixel counts against time. The perfusion of protein (50l at t
0, flow rate 5l/s) is indicated by the dark bar and arrow above the graphs. The loss of binding of 400–503 is clearly faster than loss of binding of 400–506. Average of 5 experiments/curve are
shown. Ci, Cii, Replicate curves of five experiments as in A,B are shown. Each curve is an average of3 beads per experiment. Ciii, Civ, The curves from the left panels were fitted (after t 120 s,
to allow for complete washout of unbound protein), to the two-compartment model for dissociation under flow conditions (Schuck and Minton, 1996; de Mol and Fischer, 2008). In the examples
shown for 400–503 (top) and 400–506 (bottom), the raw data (blue solid line), the fitted curve (orange dotted line), and the residual between the two (green solid line) are plotted. Background
fluorescence from the beads before addition of protein is relatively stable after a brief transience and therefore should not affect the fit to the decay curves starting at 120 s. Cv, Based on curves
obtained (A–Cii) fitted to themodel (Ciii, Civ), values for koff, kon, and Kd, obtained for binding of nNOS to both NOS1AP 400–503 and 400–506, are shown.D, Fluorescence polarization was used
to determine solution binding of fluoresceinated NOS1AP 400–506 to nNOS (1–155), giving small polarization changes as expected for such a large ligand. The data (n 3, mean SEM) were
fitted to a curve as described in Materials and Methods, giving a Kd of 0.051M.
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Residues E429/F431 are critical for affinity of
TAT-NOS1AP[400–503] to the N terminus of nNOS
To explore whether the ExF motif might be a basis for neuropro-
tection, we first determined the affinities of the TAT-fused frag-
ments of NOS1AP for their target in the N terminus of nNOS.
Increasing concentrations of recombinant TAT peptides were
incubated with immobilized GST-nNOS[1–155] on beads, re-
vealing saturable binding (Fig. 9Ci–Cii) with Kd values of
1M
forHis-TAT-NOS1AP[400–506] and5 lower affinity for the
NOS1AP[400–503] form lacking the PDZ ligand motif (Fig.
9Ciii). This difference is consistent with that determined with
fragments lacking His/TAT using the bead binding assay (Fig. 5),
although the actual affinities are somewhat lower. In contrast,
engineering inactivating mutations in the ExF site of TAT-
NOS1AP[400–503], at either E429 or F431, respectively (Fig. 7),
almost abolished binding (Fig. 9C). ThisTAT-NOS1AP[400–503]
Figure 6. NOS1AP translocates nNOS in intact cells in amanner dependent on residues 400–431 but not the PDZmotif 504–506.A, COS7 cells were transfectedwith Cherry and EGFP vectors or
plasmids encoding Cherry fusions with NOS1AP sequences (400–506, 400–503, 432–506) and EGFP fusions with nNOS 1–155 as indicated.B, Schematic model depicting the behavior of proteins
used.Bi, All C-terminal fragments of NOS1AP used, in fusionwith Cherry, reside predominantly outside the nucleus.Bii, EGFP-nNOS 1–155 enters both cytoplasmic and nuclear compartments.Biii,
When both are expressed, NOS1AP localization is unchanged, but nNOS 1–155 is largely excluded from the nuclei, suggesting the formation of nNOS-NOS1AP complexes that, like NOS1AP, do not
freely enter thenucleus.Biv, Deleting regionsofNOS1AP thatdisruptnNOS interaction is predicted toallownNOS toenter thenucleus. Thus, deletingNOS1AP residues400–431eliminates theeffect
of NOS1AP on nNOS relocalization, whereas NOS1AP lacking the PDZmotif, residues 504–506, retains nNOS relocalization. C, Experiments were performed as inA using NOS1AP residues 432–503,
lacking both PDZmotif 504–506 and the 400–432 region that appears to be required for interactionwith nNOS, fused to Cherry fluorescent protein and EGFP vector (Ci–Ciii) or EGFP-nNOS1–155
(Civ–Cvi). Cherry-NOS1AP 432–503 resided predominantly in cytoplasm (Ci, Civ), but EGFP-nNOS was present in both nuclear and cytoplasmic compartments (Cv, Cvi).
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Figure 7. Alanine scans reveal a critical ExF motif for interaction of NOS1AP with nNOS in pull-down and cell-based protein translocation assays. A, Evolutionary conservation analysis (using
ConSurf, Ashkenazy et al., 2010) of NOS1AP region 400–506 shows hotspots of evolutionary conservation at the PDZ ligandmotif (503–506), a central zone, and a region between 420 and 432. The
latter shows as a predicted  sheet using several secondary structure prediction tools (JPRED3, PSIPRED). B, Alignment of conserved region 420–432 showing the panel of alanine mutants
generated in NOS1AP constructs. C, The alanine scan panel of NOS1AP shown in B was used in a modified pull-down using a filter plate and aspiration manifold to facilitate the handling of larger
numbers of samples. NOS1AP 400–506 was defined as 100% binding; and as expected, the negative control NOS1AP 432–506 failed to interact. This analysis revealed the clearest loss of binding
inNOS1AP 400–506mutants E429A and F431A (n 4, two-wayANOVA followedbyNewman-KeulsMultiple Comparison Post Hoc Test).D, TheCOS7cell-basedassay shown inFigure6wasusedwith
the alanine mutants shown in B, C, and nuclear translocation indices (ratio of pixel intensities from segmented cytoplasmic and nuclear compartments defined as described in (Figure legend continues)
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was effective at 1M on neuronal p38MAPK activation (Fig. 9A,B)
but has5 M affinity for nNOS[1–155] (Fig. 9C). This apparent
discrepancymaymerely represent the known accumulation of TAT
peptide in cells (Wadia and Dowdy, 2005) and/or the increased ac-
tivity after in-cell refolding (Becker-Hapak et al., 2001).
Neuroprotection in organotypic slice cultures can be achieved
with TAT-fused peptides lacking the PDZ ligand if the ExF
motif is intact
Next, we addressed the impact of the TAT peptides on the nega-
tive consequences of NMDA receptors in a more physiological
setting than dissociated culture as used in Figure 9A, B. We eval-
uated neuroprotection from NMDA-induced lesions in organo-
typic hippocampal slice cultures, which possess an intact network
of neurons retaining some characteristic in vivo architecture of
cell arrangement andmorphology and has been useful for study-
ing excitotoxicity (D’Orsi et al., 2012). A substantial lesion, visu-
alized by propidium iodide, was detected 24 h after NMDA
treatment (50 M, 30 min) in CA1, CA3, and DG (Fig. 9D).
Pretreatment with PDZ motif ligand TAT-GESV demonstrated
significant reductions in CA1/CA3 staining but not in DG. Pep-
tide TAT-NOS1AP[400–503], lacking the PDZ ligandmotif, sig-
nificantly reduced staining not only in CA1/CA3 but also in DG
(Fig. 9D,E). TAT-NOS1AP[400–506], possessing intact ExF and
PDZ ligandmotifs, showed the greatest CA1 protection, as well as
reducing staining of CA3/DG (Figs. 9D,E). As controls to evalu-
ate whether the ExF motif is truly relevant to the protection in
multiple regions evoked by the peptide lacking the PDZ ligand
motif, we compared the effects of the two NOS1AP[400–503]
peptides bearing mutations at either E429 or F431 that ablate
binding of the TAT peptides to nNOS (Fig. 9C). Consistent with
our proposal that two sites are required for excitotoxic lesions,
the ExF mutant peptides did not significantly reduce NMDA-
induced propidium iodide of any slice region evaluated.
4
(Figure legend continues.) Materials and Methods) obtained from transfected cells in the
images. Once again, the clearest loss of translocating effect was observed with NOS1AP 400–
503 mutants E429A and F431A (n 4, one-way ANOVA followed by Newman-Keuls Multiple
Comparison Post Hoc Test). E, The alanine mutant panel (in luciferase-fused NOS1AP[400–
506]) was coexpressed with GST-fused nNOS[1–155]. Cell lysates were incubated with gluta-
thione beads to immobilize nNOS, and pulled down using a conventional protocol.
Coprecipitated NOS1AP was measured by luciferase assay of washed beads and normalized to
initial levels in each sample. Equal precipitation of nNOS was confirmed by immunoblotting.
This revealed loss of binding across the alanine mutant panel as in D (n 3, one-way ANOVA
followedbyNewman-KeulsMultiple ComparisonPostHoc Test). **p
0.01. ***p
0.001. ns,
Not significant.
Figure 8. Evolutionary conservation of ExFmotif among NOS1AP homologs possessing C-terminalx*motif. NOS1AP homologs containing the C-terminal PDZmotif were identified by blast
search, and evolutionary diverse examples are includedwithmammalian sequences for alignment. This revealed identity (*)was retained in only 4 residues surrounding the ExFmotif, including E429 (human
numbering), although F431 only exhibited a conservative substitution to Y in birds and some reptiles.We foundnoNOS1APhomologs possessing only the PDZmotif,without ExFmotif.
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Figure9. TheExFmotif region canbeused to reduceexcitotoxic lesions inmultiplehippocampal regions.Ai, Cortical neuron cultureswere incubatedwith cell-permeant TATpeptidesor TATalone
(1M) as shown and treated with NMDA (50M, 10 min). Activation of p38 was detected by phospho-p38 Western blotting (top), and pan-p38 antibody as loading control (bottom). Aii, The
TAT-NOS1AP 400–506 and 400–503, expressed as His-tag fusions purified by immobilizedmetal-affinity chromatography, were evaluated for purity by Coomassie staining; shorter peptides were
synthesized and quality controlled commercially. B, Quantified data show inhibition of NMDA-evoked p38 activation by TAT-GESV as previously reported as well as by NOS1AP 400–506, which
contains both ExFmotif and PDZ ligandmotif; and 400–503, which contains ExFmotif but lacks the PDZ ligandmotif (n 3, one-way ANOVA followed by Newman-Keuls (Figure legend continues)
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Discussion
We have shown here that NOS1AP interacts with the N-terminal
region of nNOS via a novel internal “ExF” motif, in contrast to
the classical PDZ docking assumed to be responsible. The affinity
of the NOS1AP C-terminal motif for the PDZ binding pocket is
nearly 1 mM, which is not considered a significant interaction.
However, in the presence of an internal region containing the
“ExF” motif, the C-terminal PDZ ligand motif increases the life-
time of the nNOS-NOS1AP complex, which appears to be a crit-
ical parameter to initiate signaling.
Interaction between NOS1AP and nNOS is increasingly cited
as a potential drug target in a growing number of diseases, includ-
ing cardiovascular and psychiatric conditions, such as schizo-
phrenia and anxiety disorders (Weber et al., 2014; Zhu et al.,
2014). It is a downstream component of the excitotoxic NR-
PSD95-nNOS pathway (Cao et al., 2005; Li et al., 2013). This
pathway is the target of the only neuroprotectant that has been
successful in a clinical trial for stroke (NA-1) (Hill et al., 2012). It
has furthermore been implicated in models of neuropathic pain
and depression (Florio et al., 2009; LeBlanc et al., 2010; Doucet et
al., 2013) and neurodegenerative diseases from Alzheimer’s and
Huntington’s to Parkinson’s disease (Ittner et al., 2010; Fan et al.,
2012; Hu et al., 2014), as has p38MAPK activation (LeBlanc et al.,
2010; Fan et al., 2012; Xu et al., 2014; Zhou et al., 2014). Most
known actions of NOS1AP, from activation of DexRas, iron
transport, and p38MAPK downstream of NMDA receptor acti-
vation (Fang et al., 2000; Cheah et al., 2006; Li et al., 2013), to
regulation of cardiac action potential (Chang et al., 2008; Kapoor
et al., 2014) and neurite outgrowth (Carrel et al., 2009) are
thought to depend on interaction with nNOS (for review, see
Courtney et al., 2014). It is therefore essential to understand the
mechanisms of interaction between nNOS and NOS1AP.
NMR structural analysis of the MelR ligand docked in the
nNOS-PDZ domain clearly shows a canonical PDZ interaction
with three C-terminal ligand residues apposed to residues lining
the PDZ pocket formed by the B sheet and B helix (Tochio et
al., 1999, shown here in Fig. 1A; Harris and Lim, 2001). NOS1AP
was also thought to bind nNOS via a canonical PDZ interaction
(Christopherson et al., 1999; Tochio et al., 1999). However, three
different binding methods clearly show the C-terminal PDZmo-
tif ofNOS1AP,which does not even conform to the nNOS class of
PDZ motifs, has little or no affinity for nNOS (Figs. 1B, 2; and
ITC data not shown). However, full-length NOS1AP protein
quantitatively relocalizes nNOS in intact cells. Furthermore,
NOS1AP binds even low levels of immobilized nNOS, yielding
high recoveries compared with other PDZ interactions, after re-
peated washing. Paradoxically, this recovery is highly dependent
on the last three C-terminal residues of NOS1AP (Fig. 1). Resi-
dues upstream of the three C-terminal ones often contribute to
PDZ interactions, typically due to additional interaction energies
conferred by residues 4–7 from the C terminus docking into a
2-3 loop (Birrane et al., 2003; Thomas et al., 2008; Lee and
Zheng, 2010; Luck et al., 2012). However, even the 9 residue
peptide from theC terminus ofNOS1AP completely fails to show
affinity for nNOS. In contrast, we detect interaction even when
deleting the last three residues. This is quite contrary to expecta-
tion for a PDZ interaction.
We addressed this paradox by deletion mapping, revealing a
critical requirement for a binding region of NOS1AP far up-
stream of the C terminus. This does not merely stabilize the PDZ
motif nor act via a third binding partner but is alone sufficient for
interaction with the N-terminal region of nNOS in the complete
absence of the PDZ motif. The PDZ motif requirement in con-
ventional pull-down assays is explained by the secondary contri-
bution of the PDZ motif to stability of the complex by reducing
off-rate. Nevertheless, in intact cells, this stability is not required
to visualize the functional consequences of interaction, specifi-
cally the relocalization of nNOS N terminus by NOS1AP frag-
ments bearing the internal binding region. Alanine scanning an
evolutionary conserved stretch of NOS1AP within the internal
binding region revealed Glu-429 and Phe-431 as critical for in-
teraction with the N terminus of nNOS. All NOS1AP homologs
we could find containing the C-terminal PDZ ligand motif also
possessed an ExF/Y motif (Fig. 8), suggesting a functional rela-
tionship between these two motifs. Furthermore, predicted
mammalian NOS1AP variants, such as XP_007974555, possess
an alternate C terminus starting immediately after amino acid
419, further suggesting that residues starting close to 420 and
ending at 506 might cooperate to confer a discrete function.
The results suggests that the primary interaction between
NOS1AP and nNOS is not the PDZ motif interaction but a sep-
arate interaction involving sequences around and including res-
idues 429/431 (“ExF motif”) sufficient to mediate binding,
whereas the PDZ motif increases the interaction lifetime. There-
fore, the effects of deleting C-terminal residues from NOS1AP
(e.g., Carrel et al., 2009) may not merely implicate nNOS but the
requirement for a long-lived interaction, a significant factor in
signal propagation. We showed that a ligand for the nNOS-PDZ
ligand-binding pocket inhibits coimmunoprecipitable nNOS:
NOS1AP induced by excitotoxic stimulation and that, in this
case, the competition at the binding pocket is sufficient to inhibit
downstream signaling (p38MAPK activation and excitotoxic
death) (Li et al., 2013).
Thus, PDZ ligand-binding pocket interaction is not necessary
for visually detectable recruitment of nNOS N terminus in living
cells (Fig. 7), but competition at the PDZ interaction interface is
effective at inhibiting neuronal kinase pathways (Li et al., 2013).
This apparent discrepancy most likely depends on the time re-
quired for activation of the kinase pathway, which takes some
minutes to reach a peak (Cao et al., 2005). Multivalent binding, a
more general form of the heterodivalent binding described here,
is common in tyrosine kinase signaling and is thought to result in
highly specific yet dynamic binding (de Mol and Fischer et al.,
2008). The same might therefore be predicted for nNOS-
NOS1AP interaction and, consistent with this, the interaction is
4
(Figure legend continues.) Multiple ComparisonPost Hoc Test). Ci, Representative fluorescent
immunoblot images showing binding of His-TAT-NOS1AP to GST-nNOS[1–155], incubated at
increasing concentrations of peptide as indicated. Bound peptide was detected by NOS1AP
primaryantibodyandanOdyssey infrared imaging system.Cii, Binding curves fromreplicates of
experiments shown in Ci, with each data point background-corrected and normalized to inter-
nal standards on each gel for each peptide. Data aremean SEM; n 3. Curveswere fitted to
data as described in Materials and Methods. Ciii, Affinity constants were obtained by fitting
each replicate for each peptide. Data aremean SEMKd values (inM). A value for Bmax could
not be reliably obtained for the His-TAT-NOS1AP[400–503]mutants due toweak binding, and
the Bmax from His-TAT-NOS1AP[400–503] wild-type was applied in these cases (see Materials
andMethods).D, Organotypic hippocampal slice cultures were incubated with TAT peptides as
indicated, at 1M; Coomassie gel shown in Di. Dii, At 24 h after 50M NMDA exposure for 30
min, lesions were visualized by incubation with the live cell-impermeant DNA stain propidium
iodide. E, Lesions, determined by propidium iodide staining (seeMaterials andMethods), were
significant in CA1, CA3, and DG. They were reduced by TAT-GESV (CA1 and CA3 only) as well as
TAT fusions ofNOS1APpeptides, including ExFmotifwith (400–506) orwithout (400–503) the
PDZ ligandmotif (all regions).However,mutationof either E429or F431 in theExFmotif renders
the reduction in lesion to a minimal nonsignificant level in all regions (n 4–8, one-way
ANOVA and Newman-Keuls Multiple Comparison Post Hoc Test). *p
 0.05. ***p
 0.001. ns,
Not significant.
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highly inducible (Li et al., 2013). This kinetic property influences
and may facilitate opportunities for development of inhibitory
strategies.
These results suggest that the PDZ-binding motif is not the
only nNOS interaction available for targeting to achieve disrup-
tion of excitotoxic or other nNOS/NOS1AP-dependent signaling
events, which may contribute to a variety of disorders for which
there are insufficient treatments available (Zhou and Sheng,
2013; Weber et al., 2014; Zhu et al., 2014). The ExF motif inter-
action mapped here may present additional opportunities for
pharmacologicalmanipulation in some or all of these conditions.
Here we find evidence that fragments of NOS1AP containing the
ExFmotif but lacking the PDZ ligandmotif can indeed be used as
pharmacological agents inhibiting excitotoxic lesions in hip-
pocampal tissue, suggesting the ExF interaction should be con-
sidered as a novel drug target.
Recruitment ofNOS1AP tonNOS is inducible (Li et al., 2013),
and the ability to disrupt signaling by competition at either by the
PDZ ligand motif or the ExF-containing region alone (Fig. 8)
indicates that both interaction sites are required for signal trans-
duction in this case. However, among NMDA signaling-related
conditions for which new interventions should be developed,
there may be cases where simultaneous competition at both sites
(and perhaps even more sites) is necessary to prevent down-
stream signaling. Furthermore, specific examples exist where
combinatorial inhibition at two sites on a target protein provides
substantial increase in inhibitor potency (Petros et al., 2010). This
possibility has also been proposed for proteins containing multi-
ple PDZ domains (Klosi et al., 2007). An increase in the number
of potential sites for therapeutic intervention can only help the
development of future therapeutic approaches. One may specu-
late that a multitarget approach may even provide the opportu-
nity to build in redundancy into an inhibitory strategy to increase
the chances of improved outcomes.
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